Using a population-based analysis to determine the management and treatment of early-stage small-cell lung cancer
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Small Cell
©2016 American Society of Clinical Oncology. Decades of randomized clinical trials have led to the development of a clear treatment approach for patients with limited-stage or extensive-stage small-cell lung cancer (SCLC). The standard first-line chemotherapy regimen is cisplatin or carboplatin plus etoposide, with the addition of radiation therapy for patients with limited-stage SCLC whose cancer is confined to the chest in a single tolerable radiation field. Patients with limited- And extensive-stage SCLC who demonstrate a response to first-line platinum-based therapy generally are offered prophylactic cranial irradiation (PCI), which has been shown to decrease the risk of intracranial recurrence and improve overall survival.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency